Vanguard Capital Management
SPRO icon

Vanguard Capital Management’s Spero Therapeutics SPRO Stock Holding History

Vanguard Capital Management’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.5M Buy
2,036,226
+236,346
+13% +$618K ﹤0.01% 3160
2026
Q1 		$4.21M Buy
+1,799,880
New +$4.27M ﹤0.01% 3126

Other funds holding SPRO

GP
GSK plc London $602M AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Vanguard Capital Management's SPRO Position: Q2 2026 in Review

Vanguard Capital Management increased its Spero Therapeutics (SPRO) stake by 13% in Q2 2026, buying an estimated $618K and bringing the position to 2,036,226 shares worth $4.5M. The position accounts for ﹤0.01% of the portfolio, ranked #3160.

Vanguard Capital Management first reported a position in SPRO in Q1 2026 and has held it in 2 quarters since. 60 funds tracked by Wall St. Rank hold SPRO as of Q2 2026.

  • Vanguard Capital Management held 2,036,226 shares of Spero Therapeutics worth $4.5M as of Q2 2026.
  • Vanguard Capital Management bought 236,346 Spero Therapeutics shares in Q2 2026, an estimated $618K.
  • Spero Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #3160 holding.
  • Vanguard Capital Management first reported a position in Spero Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 60 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.